- Trials with a EudraCT protocol (226)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (4)
226 result(s) found for: Temozolomide.
Displaying page 1 of 12.
EudraCT Number: 2013-001697-17 | Sponsor Protocol Number: A-94-52030-268 | Start Date*: 2014-05-23 |
Sponsor Name:Ipsen Pharma GmbH | ||
Full Title: PHASE II, MULTICENTRE, OPEN LABEL STUDY TO EVALUATE THE EFFICACY OF THE COMBINATION OF LANREOTIDE AUTOGEL 120 MG AND TEMOZOLOMIDE IN PATIENTS WITH PROGRESSIVE GASTRO-ENTERO-PANCREATIC NEUROENDOCRIN... | ||
Medical condition: metastatic functioning and non-functioning entero-pancreatic tumours | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Completed) DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2015-002675-19 | Sponsor Protocol Number: TMZ-CSF-001 | Start Date*: 2015-10-06 |
Sponsor Name:Medical University of Vienna, Department of Pediatrics | ||
Full Title: Pharmacokinetics of temozolomide in cerebrospinal fluid in children with malignant brain tumors | ||
Medical condition: Recurrent malignant childhood central nervous system tumors | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: AT (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-005177-29 | Sponsor Protocol Number: EORTC 26052-22053 | Start Date*: 2006-11-10 | |||||||||||
Sponsor Name:EORTC | |||||||||||||
Full Title: Phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma | |||||||||||||
Medical condition: Patients with Glioblastoma Multiforme | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) GB (Completed) FR (Completed) LV (Completed) NL (Completed) SI (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005437-32 | Sponsor Protocol Number: ERASE-TMZ | Start Date*: 2021-03-10 | ||||||||||||||||
Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI" | ||||||||||||||||||
Full Title: Temozolomide and irinotecan consolidation in patients with MGMT silenced, microsatellite stable colorectal cancer with persistence of minimal residual disease in liquid biopsy after standard adjuva... | ||||||||||||||||||
Medical condition: Stage II (pT4)/III colorectal cancer with positive circulating tumor DNA (ctDNA) after oxaliplatin-based adjuvant chemotherapy | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IT (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2006-004635-30 | Sponsor Protocol Number: UCL-ONCO-06-004 | Start Date*: 2008-11-20 |
Sponsor Name:CENTRE DU CANCER - CLINIQUES UNIVERSITAIRES SAINT-LUC | ||
Full Title: A randomized multicentric phase II study of prolonged adjuvant Temozolomide or "stop and go" in glioblastoma patients : the PATSGO study. | ||
Medical condition: It is an open-label, randomised multicentric phase II study of prolonged adjuvant Temozolomide versus "stop and go" in glioblastoma patients. This study will include a total of 70 patients. The st... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2019-002931-27 | Sponsor Protocol Number: I3Y-MC-JPCS | Start Date*: 2020-10-03 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: A Phase 1b/2 Study of Abemaciclib in Combination with Irinotecan and Temozolomide (Part A) and Abemaciclib in Combination with Temozolomide (Part B) in Pediatric and Young Adult Patients with Rela... | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Pediatric and Young Adult Patients Relapsed/Refractory Solid Tumors | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: BE (Ongoing) DE (Ongoing) IT (Ongoing) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-004438-24 | Sponsor Protocol Number: M14-483 | Start Date*: 2015-06-23 | ||||||||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | ||||||||||||||||||
Full Title: INTELLANCE 2: ABT-414 alone or ABT-414 plus temozolomide versus lomustine or temozolomide for recurrent glioblastoma: a randomized phase II study of the EORTC Brain Tumor Group. | ||||||||||||||||||
Medical condition: Glioblastoma Multiforme For Pediatric - High Grade Glioma and DIPG | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Completed) DE (Completed) HU (Completed) AT (Completed) FI (Completed) GB (Completed) IE (Completed) ES (Prematurely Ended) BE (Completed) CZ (Completed) FR (Completed) PL (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2021-004734-11 | Sponsor Protocol Number: J1S-MC-JP04 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: A Randomized, Open-Label, Phase 2 Study Evaluating Abemaciclib in Combination with Irinotecan and Temozolomide in Participants with Relapsed or Refractory Ewing's Sarcoma | |||||||||||||
Medical condition: Ewing's Sarcoma | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) IT (Ongoing) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-003066-40 | Sponsor Protocol Number: CLDE225C2301 | Start Date*: 2013-02-25 | |||||||||||
Sponsor Name:Novartis Pharma Services AG | |||||||||||||
Full Title: A Phase II, multi-center, open-label, single-arm study of the efficacy and safety of oral LDE225 versus temozolomide in patients with Hh-pathway activated relapsed medulloblastoma | |||||||||||||
Medical condition: Relapsed medulloblastoma characterised by Hedgehog (Hh)-pathway activation | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) IT (Completed) ES (Completed) DE (Completed) GB (Completed) FR (Completed) NL (Completed) BE (Completed) HU (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-002925-39 | Sponsor Protocol Number: 040826 | Start Date*: 2005-02-02 |
Sponsor Name:Kliniken för onkologi, Karolinska Universitetssjukhuset, Solna | ||
Full Title: A Phase II study of Temozolomide (Temodal) Given Continously 100mg/m2 for 21 Days in 28 Day cycles in Patients with Metastatic Melanoma. | ||
Medical condition: Metastatic melanoma | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2006-005077-21 | Sponsor Protocol Number: DCOG 0423 | Start Date*: 2007-02-12 |
Sponsor Name:Dutch Childhood Oncology Group (DCOG) | ||
Full Title: A Phase II study of concurrent radiation and Temozolomide followed by Temozolomide and Lomustine (CCNU) in the treatment of Children with High Grade Glioma | ||
Medical condition: High grade glioma: anaplastic astrocytoma, glioblastoma multiforme, gliosarcoma | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2018-000095-15 | Sponsor Protocol Number: OCTO_090 | Start Date*: 2018-11-02 | |||||||||||
Sponsor Name:University of Oxford | |||||||||||||
Full Title: A Phase II, Open Label, Randomised Study of Ipilimumab With Temozolomide Versus Temozolomide Alone after Surgery and Chemoradiotherapy in Patients with Recently Diagnosed Glioblastoma (IPI-GLIO) | |||||||||||||
Medical condition: Glioblastoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-001216-19 | Sponsor Protocol Number: | Start Date*: 2014-11-13 |
Sponsor Name:NHS Greater Glasgow & Clyde [...] | ||
Full Title: Short-course radiotherapy plus olaparib for newly diagnosed glioblastoma in patients unsuitable for radical chemoradiation: a randomised phase II clinical trial preceded by a lead-in phase I dose e... | ||
Medical condition: glioblastoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2006-001533-17 | Sponsor Protocol Number: EORTC26053-22054 | Start Date*: 2007-06-25 | |||||||||||
Sponsor Name:EORTC European Organisation for research and treatment of cancer | |||||||||||||
Full Title: Phase III trial on Concurrent and Adjuvant Temozolomide chemotherapy in non-1p/19q deleted anaplastic glioma. The CATNON Intergroup trial. | |||||||||||||
Medical condition: anaplastic glioma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) DE (Completed) FR (Completed) IT (Completed) BE (Completed) ES (Completed) GB (GB - no longer in EU/EEA) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-006146-26 | Sponsor Protocol Number: BO21990 | Start Date*: 2009-05-11 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A randomized, double blind, placebo controlled, multicenter Phase III trial of bevacizumab, temozolomide and radiotherapy, followed by bevacizumab and temozolomide versus placebo, temozolomide and ... | |||||||||||||
Medical condition: Glioblastoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) PT (Completed) DE (Completed) GB (Completed) BE (Completed) ES (Completed) HU (Completed) NL (Completed) SE (Completed) DK (Completed) IT (Completed) GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003739-37 | Sponsor Protocol Number: CA209-498 | Start Date*: 2016-05-27 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Randomized Phase 3 Open Label Study of Nivolumab vs Temozolomide Each in Combination with Radiation Therapy in Newly Diagnosed Adult Subjects with Unmethylated MGMT (tumor 06-methylguanine DNA me... | |||||||||||||
Medical condition: Unmethylated MGMT (tumor O-6-methylguanine DNA methyltransferase) Glioblastoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) AT (Completed) BE (Completed) DE (Completed) SE (Completed) ES (Ongoing) PL (Completed) DK (Completed) GB (GB - no longer in EU/EEA) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-001768-60 | Sponsor Protocol Number: CNS 2007 04 | Start Date*: 2007-10-01 | |||||||||||
Sponsor Name:University of Birmingham | |||||||||||||
Full Title: A Phase II Multi-Centre Study of Concomitant and Prolonged Adjuvant Temozolomide with Radiotherapy in Diffuse Pontine Gliomas | |||||||||||||
Medical condition: Diffuse pontine glioma in children | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001690-16 | Sponsor Protocol Number: BORTEM-17 | Start Date*: 2018-05-29 |
Sponsor Name:Helse Bergen HF | ||
Full Title: Bortezomib sensitization of recurrent glioblastoma with unmethylated MGMT promoter to Temozolomide phase 1B/II study | ||
Medical condition: recurrent or progressed WHO grade IV intracranial glioblastoma | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NO (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2013-002524-16 | Sponsor Protocol Number: 240562-2013-01 | Start Date*: 2014-01-10 |
Sponsor Name:Dept of Oncology. Haukeland University Hospital | ||
Full Title: Everolimus and temozolomide as first-line treatment in advanced gastrointestinal neuroendocrine carcinoma (G3) with a Ki67 of 20-55% | ||
Medical condition: Everolimus and temozolomide as first-line treatment in advanced gastrointestinal neuroendocrine carcinoma (G3) with a Ki67 of 20-55% | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Completed) DK (Completed) | ||
Trial results: View results |
EudraCT Number: 2007-003254-28 | Sponsor Protocol Number: 782/07 | Start Date*: 2008-03-15 | |||||||||||
Sponsor Name:POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI | |||||||||||||
Full Title: RADIOCHEMIOTERAPIA CON TEMOZOLOMIDE CONCOMITANTE E ADIUVANTE NEL TRATTAMENTO DEI LINFOMI CEREBRALI PRIMITIVI DOPO METOTREXATE AD ALTE DOSI: STUDIO DI DOSE ESCALATION | |||||||||||||
Medical condition: primary central nervous lymphoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.